Sat02222020

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • IT Career News
    IT Career News
  • Microsoft Exam
    Microsoft Exam
  • Youtube Marketing Guide
    Youtube Marketing Guide
  • Slot Game Review
    Slot Game Review
  • All Elite Wrestling
    All Elite Wrestling

RobinsPost News Network

+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray


JERSEY, Channel Islands, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray.

“We are very pleased to report the CE Mark approval of the Initial SDS Microarray ahead of our guidance. This is our third market clearance and the CE certification of our second Microarray within a year marks an important leap forward for our Company as we continue to expand both our Serological Disease Screening and Immunohematology (IH) menus. The Initial SDS and Expanded IH Microarrays will be the first powerful commercial combination for the Company,” said Franz Walt, Chief Executive Officer of Quotient.

About Quotient Limited 
Building on 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the application of MosaiQ to infectious disease diagnostics), and the timing of the issuance of the Company's additional notes. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding; continued or worsening adverse conditions in the general domestic and global economic markets; the Company's ability to satisfy certain closing conditions associated with the issuance of the additional notes; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT:

Peter Buhler, Chief Financial Officer – This email address is being protected from spambots. You need JavaScript enabled to view it.; 41 22 545 52 26

or

Christopher Lindop, Executive Vice President - This email address is being protected from spambots. You need JavaScript enabled to view it.; +41 799 61 69 38



Posted: 2020-02-14 13:04:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF
'
'


Related News Stories From The Web And More

Related Bing News

Press Release: Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Quotient receives CE mark approval for the Initial Serological Disease Screening Microarray

Fri, 14 Feb 2020 10:53:00 GMT

Quotient (NASDAQ:QTNT) has received the CE Mark approval for the Initial Serological Disease Screening Microarray. This approval is Quotient's third market clearance and the CE certification of ...

Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray

Fri, 14 Feb 2020 05:08:00 GMT

Mark approval for the Initial Serological Disease Screening (SDS) Microarray. “We are very pleased to report the CE Mark approval of the Initial SDS Microarray ahead of our guidance. This is our ...

Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray

Fri, 14 Feb 2020 05:04:00 GMT

JERSEY, Channel Islands, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the ...

Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results

Thu, 30 Jan 2020 03:42:00 GMT

microarray, the US Food and Drug Administration's (FDA) acceptance of its 510(k) submission for both the initial Serological Disease Screening (SDS) microarray and the MosaiQ(TM) system and the ...

Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results

Thu, 30 Jan 2020 03:00:00 GMT

Submission Accepted Commencement of EU Expanded Immunohematology Field Trial Activities Continued Strong Top Line Growth in the Quarter and Year to Date JERSEY, Channel Islands, Jan. 30, 2020 (GLOBE ...

Related News Story Videos From Youtube

  • This Service Is Coming Soon.





  • Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2020 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources:
    Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.